Quest Diagnostics price target lowered to $145 from $150 at Truist

Truist analyst David MacDonald lowered the firm’s price target on Quest Diagnostics to $145 from $150 and keeps a Hold rating on the shares. The company’s Q4 results were somewhat mixed, featuring top-line strength and solid base business trends while margins came shy of the firm’s estimates, the analyst tells investors in a research note. Truist adds however that the company’s financial flexibility remains solid, and it expects an ongoing tailwind from health system opportunities and a robust pipeline of potential M&A.